TransMedics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
February 26, 2024 at 04:20 pm
Share
TransMedics Group, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 241.62 million compared to USD 93.46 million a year ago. Net loss was USD 25.03 million compared to USD 36.23 million a year ago.
Basic loss per share from continuing operations was USD 0.77 compared to USD 1.23 a year ago. Diluted loss per share from continuing operations was USD 0.77 compared to USD 1.23 a year ago.
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.